Mechanisms of Action in cGVHD Therapy: Why the Target Matters

Brook Adams, PharmD, BCOP, explains axatilimab's distinct mechanism targeting the CSF1R pathway on macrophages and monocytes—as opposed to T-cell pathways (ibrutinib) or JAK/STAT signaling (ruxolitinib)—and why this mechanistic differentiation is clinically meaningful when patients have already progressed on other agents.